DBV Technologies SA (DBV) Stock Price & News

DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia

About DBV Technologies SA

CEO-

Employees179

FoundedMar 29, 2002

Headquarters-

SectorHealth Care

IndustryBiotechnology

Websitedbv-technologies.com

All values in USD	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Revenue	645.00K	900.00K	700.00K	1.60M
Cost of goods sold	-	-	-	-
Cost of revenue	-	-	-	-
Research and development expenses	32.89M	33.40M	31.20M	47.00M
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	12.80M	15.30M	20.10M	19.30M
Operating expense	45.70M	48.70M	51.30M	66.30M
Total operating expenses	45.70M	48.70M	51.30M	66.30M
Operating income	-45.05M	-47.80M	-50.60M	-64.70M
Other non operating income	-1.00K	-100.00K	-	-100.00K
EBT including unusual items	-44.46M	-47.40M	-50.20M	-64.20M
EBT excluding unusual items	-44.46M	-47.40M	-50.20M	-64.20M
Income tax expense	374.00K	200.00K	200.00K	300.00K
Effective tax rate	-0.84%	-0.42%	-0.40%	-0.47%
Other operating expenses	-	-	-	-
Net income	-44.83M	-47.60M	-50.40M	-64.50M
Net profit margin	-6,950.23%	-5,288.89%	-7,200.00%	-4,031.25%
Earnings per share	-	-	-	-
Interest and investment income	597.00K	500.00K	400.00K	600.00K
Interest expense	-	-	-	-
Net interest expenses	597.00K	500.00K	400.00K	600.00K
Depreciation and amortization charges	-	-	-	-
EBITDA	-44.36M	-46.90M	-50.00M	-64.40M
Gain or loss from assets sale	-	-	-	-

Ask anything